Search

Your search keyword '"Hakemi M."' showing total 198 results
Start Over Author "Hakemi M."
198 results on '"Hakemi M."'

3. Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19

Author

Marto, J, Strambo, D, Ntaios, G, Nguyen, T, Herzig, R, Czlonkowska, A, Demeestere, J, Mansour, O, Salerno, A, Wegener, S, Baumgartner, P, Cereda, C, Bianco, G, Beyeler, M, Arnold, M, Carrera, E, Machi, P, Altersberger, V, Bonati, L, Gensicke, H, Bolognese, M, Peters, N, Wetzel, S, Magrico, M, Ramos, J, Sargento-Freitas, J, Machado, R, Maia, C, Machado, E, Nunes, A, Ferreira, P, Pinho E Melo, T, Dias, M, Paula, A, Correia, M, Castro, P, Azevedo, E, Albuquerque, L, Alves, J, Ferreira-Pinto, J, Meira, T, Pereira, L, Rodrigues, M, Araujo, A, Rocha, M, Pereira-Fonseca, A, Ribeiro, L, Varela, R, Malheiro, S, Cappellari, M, Zivelonghi, C, Sajeva, G, Zini, A, Gentile, M, Forlivesi, S, Migliaccio, L, Sessa, M, La Gioia, S, Pezzini, A, Sangalli, D, Zedde, M, Pascarella, R, Ferrarese, C, Beretta, S, Diamanti, S, Schwarz, G, Frisullo, G, Marcheselli, S, Seners, P, Sabben, C, Escalard, S, Piotin, M, Maier, B, Charbonnier, G, Vuillier, F, Legris, L, Cuisenier, P, Vodret, F, Marnat, G, Liegey, J, Sibon, I, Flottmann, F, Broocks, G, Gloyer, N, Bohmann, F, Schaefer, J, Nolte, C, Audebert, H, Siebert, E, Sykora, M, Lang, W, Ferrari, J, Mayer-Suess, L, Knoflach, M, Gizewski, E, Stolp, J, Stolze, L, Coutinho, J, Nederkoorn, P, Van Den Wijngaard, I, De Meris, J, Lemmens, R, De Raedt, S, Vandervorst, F, Rutgers, M, Guilmot, A, Dusart, A, Bellante, F, Calleja-Castano, P, Ostos, F, Gonzalez-Ortega, G, Martin-Jimenez, P, Garcia-Madrona, S, Cruz-Culebras, A, Vera, R, Matute, M, Fuentes, B, Alonso-De-Lecinana, M, Rigual, R, Diez-Tejedor, E, Perez-Sanchez, S, Montaner, J, Diaz-Otero, F, Perez-De-La-Ossa, N, Flores-Pina, B, Munoz-Narbona, L, Chamorro, A, Rodriguez-Vazquez, A, Renu, A, Ayo-Martin, O, Hernandez-Fernandez, F, Segura, T, Tejada-Meza, H, Sagarra-Mur, D, Serrano-Ponz, M, Hlaing, T, See, I, Simister, R, Werring, D, Kristoffersen, E, Nordanstig, A, Jood, K, Rentzos, A, Simunek, L, Krajickova, D, Krajina, A, Mikulik, R, Cvikova, M, Vinklarek, J, Skoloudik, D, Roubec, M, Hurtikova, E, Hruby, R, Ostry, S, Skoda, O, Pernicka, M, Jurak, L, Eichlova, Z, Jira, M, Kovar, M, Pansky, M, Mencl, P, Palouskova, H, Tomek, A, Jansky, P, Olserova, A, Sramek, M, Havlicek, R, Maly, P, Trakal, L, Fiksa, J, Slovak, M, Karlinski, M, Nowak, M, Sienkiewicz-Jarosz, H, Bochynska, A, Wrona, P, Homa, T, Sawczynska, K, Slowik, A, Wlodarczyk, E, Wiacek, M, Tomaszewska-Lampart, I, Sieczkowski, B, Bartosik-Psujek, H, Bilik, M, Bandzarewicz, A, Dorobek, M, Zielinska-Turek, J, Nowakowska-Kotas, M, Obara, K, Urbanowski, P, Budrewicz, S, Guzinski, M, Switonska, M, Rutkowska, I, Sobieszak-Skura, P, Labuz-Roszak, B, Debiec, A, Staszewski, J, Stepien, A, Zwiernik, J, Wasilewski, G, Tiu, C, Terecoasa, E, Radu, R, Negrila, A, Dorobat, B, Panea, C, Tiu, V, Petrescu, S, Ozdemir, A, Mahmoud, M, El-Samahy, H, Abdelkhalek, H, Al-Hashel, J, Ismail, I, Salmeen, A, Ghoreishi, A, Sabetay, S, Gross, H, Klein, P, Abdalkader, M, Jabbour, P, El Naamani, K, Tjoumakaris, S, Abbas, R, Mohamed, G, Chebl, A, Min, J, Hovingh, M, Tsai, J, Khan, M, Nalleballe, K, Onteddu, S, Masoud, H, Michael, M, Kaur, N, Maali, L, Abraham, M, Khandelwal, P, Bach, I, Ong, M, Babici, D, Khawaja, A, Hakemi, M, Rajamani, K, Cano-Nigenda, V, Arauz, A, Amaya, P, Llanos, N, Arango, A, Vences, M, Barrientos Guerra, J, Caetano, R, Martins, R, Scollo, S, Yalung, P, Nagendra, S, Gaikwad, A, Seo, K, Georgiopoulos, G, Nogueira, R, Michel, P, Marto J. P., Strambo D., Ntaios G., Nguyen T. N., Herzig R., Czlonkowska A., Demeestere J., Mansour O. Y., Salerno A., Wegener S., Baumgartner P., Cereda C. W., Bianco G., Beyeler M., Arnold M., Carrera E., Machi P., Altersberger V., Bonati L., Gensicke H., Bolognese M., Peters N., Wetzel S., Magrico M., Ramos J. N., Sargento-Freitas J., Machado R., Maia C., Machado E., Nunes A. P., Ferreira P., Pinho E Melo T., Dias M. C., Paula A., Correia M. A., Castro P., Azevedo E., Albuquerque L., Alves J. N., Ferreira-Pinto J., Meira T., Pereira L., Rodrigues M., Araujo A. P., Rocha M., Pereira-Fonseca A., Ribeiro L., Varela R., Malheiro S., Cappellari M., Zivelonghi C., Sajeva G., Zini A., Gentile M., Forlivesi S., Migliaccio L., Sessa M., La Gioia S., Pezzini A., Sangalli D., Zedde M., Pascarella R., Ferrarese C., Beretta S., Diamanti S., Schwarz G., Frisullo G., Marcheselli S., Seners P., Sabben C., Escalard S., Piotin M., Maier B., Charbonnier G., Vuillier F., Legris L., Cuisenier P., Vodret F. R., Marnat G., Liegey J. -S., Sibon I., Flottmann F., Broocks G., Gloyer N. -O., Bohmann F. O., Schaefer J. H., Nolte C., Audebert H. J., Siebert E., Sykora M., Lang W., Ferrari J., Mayer-Suess L., Knoflach M., Gizewski E. R., Stolp J., Stolze L. J., Coutinho J. M., Nederkoorn P., Van Den Wijngaard I., De Meris J., Lemmens R., De Raedt S., Vandervorst F., Rutgers M. P., Guilmot A., Dusart A., Bellante F., Calleja-Castano P., Ostos F., Gonzalez-Ortega G., Martin-Jimenez P., Garcia-Madrona S., Cruz-Culebras A., Vera R., Matute M. C., Fuentes B., Alonso-De-Lecinana M., Rigual R., Diez-Tejedor E., Perez-Sanchez S., Montaner J., Diaz-Otero F., Perez-De-La-Ossa N., Flores-Pina B., Munoz-Narbona L., Chamorro A., Rodriguez-Vazquez A., Renu A., Ayo-Martin O., Hernandez-Fernandez F., Segura T., Tejada-Meza H., Sagarra-Mur D., Serrano-Ponz M., Hlaing T., See I., Simister R., Werring D., Kristoffersen E. S., Nordanstig A., Jood K., Rentzos A., Simunek L., Krajickova D., Krajina A., Mikulik R., Cvikova M., Vinklarek J., Skoloudik D., Roubec M., Hurtikova E., Hruby R., Ostry S., Skoda O., Pernicka M., Jurak L., Eichlova Z., Jira M., Kovar M., Pansky M., Mencl P., Palouskova H., Tomek A., Jansky P., Olserova A., Sramek M., Havlicek R., Maly P., Trakal L., Fiksa J., Slovak M., Karlinski M. A., Nowak M., Sienkiewicz-Jarosz H., Bochynska A., Wrona P., Homa T., Sawczynska K., Slowik A., Wlodarczyk E., Wiacek M., Tomaszewska-Lampart I., Sieczkowski B., Bartosik-Psujek H., Bilik M., Bandzarewicz A., Dorobek M., Zielinska-Turek J., Nowakowska-Kotas M., Obara K., Urbanowski P., Budrewicz S., Guzinski M., Switonska M., Rutkowska I., Sobieszak-Skura P., Labuz-Roszak B. M., Debiec A., Staszewski J., Stepien A., Zwiernik J., Wasilewski G., Tiu C., Terecoasa E. O., Radu R. A., Negrila A., Dorobat B., Panea C., Tiu V., Petrescu S., Ozdemir A., Mahmoud M., El-Samahy H., Abdelkhalek H., Al-Hashel J., Ismail I. I., Salmeen A., Ghoreishi A., Sabetay S. I., Gross H., Klein P., Abdalkader M., Jabbour P., El Naamani K., Tjoumakaris S., Abbas R., Mohamed G. A., Chebl A., Min J., Hovingh M., Tsai J. P., Khan M., Nalleballe K., Onteddu S., Masoud H., Michael M., Kaur N., Maali L., Abraham M. G., Khandelwal P., Bach I., Ong M., Babici D., Khawaja A. M., Hakemi M., Rajamani K., Cano-Nigenda V., Arauz A., Amaya P., Llanos N., Arango A., Vences M. A., Barrientos Guerra J. D., Caetano R., Martins R. T., Scollo S. D., Yalung P. M., Nagendra S., Gaikwad A., Seo K. -D., Georgiopoulos G., Nogueira R. G., Michel P., Marto, J, Strambo, D, Ntaios, G, Nguyen, T, Herzig, R, Czlonkowska, A, Demeestere, J, Mansour, O, Salerno, A, Wegener, S, Baumgartner, P, Cereda, C, Bianco, G, Beyeler, M, Arnold, M, Carrera, E, Machi, P, Altersberger, V, Bonati, L, Gensicke, H, Bolognese, M, Peters, N, Wetzel, S, Magrico, M, Ramos, J, Sargento-Freitas, J, Machado, R, Maia, C, Machado, E, Nunes, A, Ferreira, P, Pinho E Melo, T, Dias, M, Paula, A, Correia, M, Castro, P, Azevedo, E, Albuquerque, L, Alves, J, Ferreira-Pinto, J, Meira, T, Pereira, L, Rodrigues, M, Araujo, A, Rocha, M, Pereira-Fonseca, A, Ribeiro, L, Varela, R, Malheiro, S, Cappellari, M, Zivelonghi, C, Sajeva, G, Zini, A, Gentile, M, Forlivesi, S, Migliaccio, L, Sessa, M, La Gioia, S, Pezzini, A, Sangalli, D, Zedde, M, Pascarella, R, Ferrarese, C, Beretta, S, Diamanti, S, Schwarz, G, Frisullo, G, Marcheselli, S, Seners, P, Sabben, C, Escalard, S, Piotin, M, Maier, B, Charbonnier, G, Vuillier, F, Legris, L, Cuisenier, P, Vodret, F, Marnat, G, Liegey, J, Sibon, I, Flottmann, F, Broocks, G, Gloyer, N, Bohmann, F, Schaefer, J, Nolte, C, Audebert, H, Siebert, E, Sykora, M, Lang, W, Ferrari, J, Mayer-Suess, L, Knoflach, M, Gizewski, E, Stolp, J, Stolze, L, Coutinho, J, Nederkoorn, P, Van Den Wijngaard, I, De Meris, J, Lemmens, R, De Raedt, S, Vandervorst, F, Rutgers, M, Guilmot, A, Dusart, A, Bellante, F, Calleja-Castano, P, Ostos, F, Gonzalez-Ortega, G, Martin-Jimenez, P, Garcia-Madrona, S, Cruz-Culebras, A, Vera, R, Matute, M, Fuentes, B, Alonso-De-Lecinana, M, Rigual, R, Diez-Tejedor, E, Perez-Sanchez, S, Montaner, J, Diaz-Otero, F, Perez-De-La-Ossa, N, Flores-Pina, B, Munoz-Narbona, L, Chamorro, A, Rodriguez-Vazquez, A, Renu, A, Ayo-Martin, O, Hernandez-Fernandez, F, Segura, T, Tejada-Meza, H, Sagarra-Mur, D, Serrano-Ponz, M, Hlaing, T, See, I, Simister, R, Werring, D, Kristoffersen, E, Nordanstig, A, Jood, K, Rentzos, A, Simunek, L, Krajickova, D, Krajina, A, Mikulik, R, Cvikova, M, Vinklarek, J, Skoloudik, D, Roubec, M, Hurtikova, E, Hruby, R, Ostry, S, Skoda, O, Pernicka, M, Jurak, L, Eichlova, Z, Jira, M, Kovar, M, Pansky, M, Mencl, P, Palouskova, H, Tomek, A, Jansky, P, Olserova, A, Sramek, M, Havlicek, R, Maly, P, Trakal, L, Fiksa, J, Slovak, M, Karlinski, M, Nowak, M, Sienkiewicz-Jarosz, H, Bochynska, A, Wrona, P, Homa, T, Sawczynska, K, Slowik, A, Wlodarczyk, E, Wiacek, M, Tomaszewska-Lampart, I, Sieczkowski, B, Bartosik-Psujek, H, Bilik, M, Bandzarewicz, A, Dorobek, M, Zielinska-Turek, J, Nowakowska-Kotas, M, Obara, K, Urbanowski, P, Budrewicz, S, Guzinski, M, Switonska, M, Rutkowska, I, Sobieszak-Skura, P, Labuz-Roszak, B, Debiec, A, Staszewski, J, Stepien, A, Zwiernik, J, Wasilewski, G, Tiu, C, Terecoasa, E, Radu, R, Negrila, A, Dorobat, B, Panea, C, Tiu, V, Petrescu, S, Ozdemir, A, Mahmoud, M, El-Samahy, H, Abdelkhalek, H, Al-Hashel, J, Ismail, I, Salmeen, A, Ghoreishi, A, Sabetay, S, Gross, H, Klein, P, Abdalkader, M, Jabbour, P, El Naamani, K, Tjoumakaris, S, Abbas, R, Mohamed, G, Chebl, A, Min, J, Hovingh, M, Tsai, J, Khan, M, Nalleballe, K, Onteddu, S, Masoud, H, Michael, M, Kaur, N, Maali, L, Abraham, M, Khandelwal, P, Bach, I, Ong, M, Babici, D, Khawaja, A, Hakemi, M, Rajamani, K, Cano-Nigenda, V, Arauz, A, Amaya, P, Llanos, N, Arango, A, Vences, M, Barrientos Guerra, J, Caetano, R, Martins, R, Scollo, S, Yalung, P, Nagendra, S, Gaikwad, A, Seo, K, Georgiopoulos, G, Nogueira, R, Michel, P, Marto J. P., Strambo D., Ntaios G., Nguyen T. N., Herzig R., Czlonkowska A., Demeestere J., Mansour O. Y., Salerno A., Wegener S., Baumgartner P., Cereda C. W., Bianco G., Beyeler M., Arnold M., Carrera E., Machi P., Altersberger V., Bonati L., Gensicke H., Bolognese M., Peters N., Wetzel S., Magrico M., Ramos J. N., Sargento-Freitas J., Machado R., Maia C., Machado E., Nunes A. P., Ferreira P., Pinho E Melo T., Dias M. C., Paula A., Correia M. A., Castro P., Azevedo E., Albuquerque L., Alves J. N., Ferreira-Pinto J., Meira T., Pereira L., Rodrigues M., Araujo A. P., Rocha M., Pereira-Fonseca A., Ribeiro L., Varela R., Malheiro S., Cappellari M., Zivelonghi C., Sajeva G., Zini A., Gentile M., Forlivesi S., Migliaccio L., Sessa M., La Gioia S., Pezzini A., Sangalli D., Zedde M., Pascarella R., Ferrarese C., Beretta S., Diamanti S., Schwarz G., Frisullo G., Marcheselli S., Seners P., Sabben C., Escalard S., Piotin M., Maier B., Charbonnier G., Vuillier F., Legris L., Cuisenier P., Vodret F. R., Marnat G., Liegey J. -S., Sibon I., Flottmann F., Broocks G., Gloyer N. -O., Bohmann F. O., Schaefer J. H., Nolte C., Audebert H. J., Siebert E., Sykora M., Lang W., Ferrari J., Mayer-Suess L., Knoflach M., Gizewski E. R., Stolp J., Stolze L. J., Coutinho J. M., Nederkoorn P., Van Den Wijngaard I., De Meris J., Lemmens R., De Raedt S., Vandervorst F., Rutgers M. P., Guilmot A., Dusart A., Bellante F., Calleja-Castano P., Ostos F., Gonzalez-Ortega G., Martin-Jimenez P., Garcia-Madrona S., Cruz-Culebras A., Vera R., Matute M. C., Fuentes B., Alonso-De-Lecinana M., Rigual R., Diez-Tejedor E., Perez-Sanchez S., Montaner J., Diaz-Otero F., Perez-De-La-Ossa N., Flores-Pina B., Munoz-Narbona L., Chamorro A., Rodriguez-Vazquez A., Renu A., Ayo-Martin O., Hernandez-Fernandez F., Segura T., Tejada-Meza H., Sagarra-Mur D., Serrano-Ponz M., Hlaing T., See I., Simister R., Werring D., Kristoffersen E. S., Nordanstig A., Jood K., Rentzos A., Simunek L., Krajickova D., Krajina A., Mikulik R., Cvikova M., Vinklarek J., Skoloudik D., Roubec M., Hurtikova E., Hruby R., Ostry S., Skoda O., Pernicka M., Jurak L., Eichlova Z., Jira M., Kovar M., Pansky M., Mencl P., Palouskova H., Tomek A., Jansky P., Olserova A., Sramek M., Havlicek R., Maly P., Trakal L., Fiksa J., Slovak M., Karlinski M. A., Nowak M., Sienkiewicz-Jarosz H., Bochynska A., Wrona P., Homa T., Sawczynska K., Slowik A., Wlodarczyk E., Wiacek M., Tomaszewska-Lampart I., Sieczkowski B., Bartosik-Psujek H., Bilik M., Bandzarewicz A., Dorobek M., Zielinska-Turek J., Nowakowska-Kotas M., Obara K., Urbanowski P., Budrewicz S., Guzinski M., Switonska M., Rutkowska I., Sobieszak-Skura P., Labuz-Roszak B. M., Debiec A., Staszewski J., Stepien A., Zwiernik J., Wasilewski G., Tiu C., Terecoasa E. O., Radu R. A., Negrila A., Dorobat B., Panea C., Tiu V., Petrescu S., Ozdemir A., Mahmoud M., El-Samahy H., Abdelkhalek H., Al-Hashel J., Ismail I. I., Salmeen A., Ghoreishi A., Sabetay S. I., Gross H., Klein P., Abdalkader M., Jabbour P., El Naamani K., Tjoumakaris S., Abbas R., Mohamed G. A., Chebl A., Min J., Hovingh M., Tsai J. P., Khan M., Nalleballe K., Onteddu S., Masoud H., Michael M., Kaur N., Maali L., Abraham M. G., Khandelwal P., Bach I., Ong M., Babici D., Khawaja A. M., Hakemi M., Rajamani K., Cano-Nigenda V., Arauz A., Amaya P., Llanos N., Arango A., Vences M. A., Barrientos Guerra J. D., Caetano R., Martins R. T., Scollo S. D., Yalung P. M., Nagendra S., Gaikwad A., Seo K. -D., Georgiopoulos G., Nogueira R. G., and Michel P.

Abstract

Background and Objectives COVID-19–related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19. Methods This was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). Results Of a total of 15,128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19; of those, 5,848 (38.7%) patients received IVT-only and 9,280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted OR 1.53; 95% CI 1.16–2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20–2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23–1.99), 24-hour mortality (OR 2.47; 95% CI 1.58–3.86), and 3-month mortality (OR 1.88; 95% CI 1.52–2.33). Patients with COVID-19 also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26–1.60). Discussion Patients with AIS and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non–COVID-19 patients receiving treatment. Current available data do not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in patients with COVID-19 or to establish different treatment r

Published
2023

7. Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up

Author

Nguyen, Tn, Qureshi, Mm, Klein, P, Yamagami, H, Mikulik, R, Etminan, N, Abdalkader, M, Mansour, Oy, Czlonkowska, A, Lo, H, Sathya, A, Demeestere, J, Tsivgoulis, G, Sakai, N, Sedova, P, Kristoffersen, Es, Mohammaden, M, Lereis, Vp, Scollo, Sd, Ma, A, Rahman, A, Bonnet, T, Cortier, J, De Raedt, S, Lemmens, R, Ligot, N, Hidalgo, Rct, Cuervo, Dlm, Neves, Ld, Rezende, Mts, Santiago, Ib, Sirakov, A, Sirakov, S, Cora, Ea, Kelly, Me, Lavoie, P, Peeling, L, Pikula, A, Rivera, R, Chen, Hs, Chen, Ym, Fang, Hl, Bedekovic, Mr, Budincevic, H, Strossmayer, Jj, Hrabanovska, E, Jurak, L, Cabal, M, Kadlckova, J, Karpowicz, I, Palouskova, H, Reiser, M, Klecka, L, Kovar, M, Neumann, J, Rekova, P, Sramek, M, Vitkova, E, Skorna, M, Zakova, L, Sobh, K, Alpay, K, Rautio, R, Strbian, D, Gentric, Jc, Magro, E, Naggara, O, Reiner, P, Abdulazim, A, Bohmann, Fo, Boskamp, S, Gerber, Jc, Kaiser, Dpo, Kestner, Ri, Mbroh, J, Neyazi, M, Rosenkranz, M, Sani, Af, Poli, S, Thomalla, G, Karapanayiotides, T, Kargiotis, O, Koutroulou, I, Palaiodimou, L, Guerra, Jdb, Huded, V, Nagendra, S, Prajapati, C, Krishna, A, Ghoreishi, A, Ilkhchi, Rb, Jalili, J, Sabetay, Si, Abu Raya, T, Acampa, M, Longoni, M, Bigliani, Cr, Castellan, L, Ornello, R, Renieri, L, Romoli, M, Sacco, S, Sangalli, D, Vigano, M, Zini, A, Tokimura, H, Sonoda, K, Todo, K, Fukuda, H, Fujita, K, Sakaguchi, M, Uno, M, Kan, I, Kosuke, M, Kono, R, Kimura, N, Yamamoto, N, Yamamoto, R, Doijiri, R, Shindo, S, Ohara, N, Imamura, H, Ogawa, T, Uwatoko, T, Kanamaru, T, Fujinaka, T, Takenobu, Y, Toyoda, K, Matsumaru, Y, Yazawa, Y, Sugiura, Y, Baek, Jh, Sunmonu, Ta, Kwon, Ys, Lee, Yh, Seo, Kd, Sohn, Si, Chan, Yc, Zaidi, Waw, Barrientos-Prieto, J, Gongora-Rivera, F, Martinez-Marino, M, Calderon-Vallejo, A, Groppa, S, Pavel, L, Coutinho, Jm, Dippel, D, Rinkel, L, Van Dam-Nolen, Dhk, Nwazor, Eo, Al Hashimi, Am, Ahmad, S, Rashid, U, Rodriguez-Kadota, L, Vences, Ma, Yalung, Pm, Jsh, Dy, Brola, W, Dorobek, M, Karlinski, Ma, Labuz-Roszak, Bm, Lasek-Bal, A, Sienkiewicz-Jarosz, H, Staszewski, J, Sobolewski, P, Zielinska-Turek, J, Araujo, Ap, Fonseca, L, Debiec, A, Silva, Ml, Castro, P, Rocha, M, Falup-Pecurariu, Rc, Venketasubramanian, N, Mako, Gkm, Ayo-Martin, O, Wiacek, M, Blasco, J, Cruz-Culebras, A, Hernandez-Fernandez, F, Fernandez, Cr, Lopez, Je, Rodriguez, A, Bolognese, M, Karwacki, Gm, Keller, E, Machi, P, Bernava, G, Boonyakarnkul, S, Churojana, A, Hammami, N, Bajrami, A, Senadim, S, Hussain, Si, John, S, Dow, G, Krishnan, K, Lenthall, R, Wong, K, Zhang, Lq, Altschul, D, Asif, Ks, Aziz-Sultan, Ma, Bach, I, Below, K, Biller, J, Cervantes-Arslanian, Am, Chaudhry, Sa, Chebl, A, Chen, M, Colasurdo, M, Czap, A, Dasenbrock, H, Bahiru, Z, de Havenon, Ah, Dharmadhikari, S, Dmytriw, Aa, Eskey, Cj, Etherton, M, Ezepue, C, Fink, L, Gasimova, U, Goyal, N, Grimmett, Kb, Hakemi, M, Hester, T, Inoa, V, Kan, Pt, Kasper, Em, Khandelwal, P, Khatri, R, Khoury, Nn, Kim, Bs, Kolikonda, M, Kuhn, Al, Linares, G, Linfante, I, Loochtan, Ai, Lukovits, Tg, Male, Ss, Khawaja, Am, Maali, L, Galecio-Castillo, Em, Min, Jy, Mohamed, Ga, Nalleballe, K, Ortega-Gutierrez, S, Radaideh, Y, Ramakrishnan, P, Masoud, He, Reddy, Ab, Ruland, S, Omran, Ss, Sheth, Sa, Puri, As, Rahangdale, Rh, Siegler, Je, Starosciak, Ak, Tarlov, Ne, Taylor, Ra, Tsai, J, Wang, Mj, Wong, Kh, Zaidat, Oo, Hv, Le, Phan, Ht, Ton, Md, Tran, Ad, Sirakova, K, Pham, Tn, Mohlenbruch, Ma, Nagel, S, Raymond, J, Nogueira, Rg, Neurology, ACS - Atherosclerosis & ischemic syndromes, and ANS - Neurovascular Disorders

Subjects
Psychiatry and Mental health, SDG 3 - Good Health and Well-being, COVID-19, SUBARACHNOID HAEMORRHAGE, CEREBROVASCULAR DISEASE, Surgery, Neurology (clinical)
Abstract

BackgroundPrior studies indicated a decrease in the incidences of aneurysmal subarachnoid haemorrhage (aSAH) during the early stages of the COVID-19 pandemic. We evaluated differences in the incidence, severity of aSAH presentation, and ruptured aneurysm treatment modality during the first year of the COVID-19 pandemic compared with the preceding year.MethodsWe conducted a cross-sectional study including 49 countries and 187 centres. We recorded volumes for COVID-19 hospitalisations, aSAH hospitalisations, Hunt-Hess grade, coiling, clipping and aSAH in-hospital mortality. Diagnoses were identified by International Classification of Diseases, 10th Revision, codes or stroke databases from January 2019 to May 2021.ResultsOver the study period, there were 16 247 aSAH admissions, 344 491 COVID-19 admissions, 8300 ruptured aneurysm coiling and 4240 ruptured aneurysm clipping procedures. Declines were observed in aSAH admissions (−6.4% (95% CI −7.0% to −5.8%), p=0.0001) during the first year of the pandemic compared with the prior year, most pronounced in high-volume SAH and high-volume COVID-19 hospitals. There was a trend towards a decline in mild and moderate presentations of subarachnoid haemorrhage (SAH) (mild: −5% (95% CI −5.9% to –4.3%), p=0.06; moderate: −8.3% (95% CI −10.2% to –6.7%), p=0.06) but no difference in higher SAH severity. The ruptured aneurysm clipping rate remained unchanged (30.7% vs 31.2%, p=0.58), whereas ruptured aneurysm coiling increased (53.97% vs 56.5%, p=0.009). There was no difference in aSAH in-hospital mortality rate (19.1% vs 20.1%, p=0.12).ConclusionDuring the first year of the pandemic, there was a decrease in aSAH admissions volume, driven by a decrease in mild to moderate presentation of aSAH. There was an increase in the ruptured aneurysm coiling rate but neither change in the ruptured aneurysm clipping rate nor change in aSAH in-hospital mortality.Trial registration numberNCT04934020.

Published
2022

9. Optimization of In Vitro Expansion and Activation of Human Natural Killer Cells against Breast Cancer Cell Line

Author

Peighambarzadeh, F., Najafalizadeh, A., Esmaeil, N., Rezaei, A., farzaneh Ashrafi, and Hakemi, M. G.

Subjects
Interleukins (IL), Natural killer cells, Original Article, Immunotherapy
Abstract

Background: Regarding to the increase of cancer deaths in recent years and disability of common therapies to eradicate cancers, as well as expansion of Natural Killer (NK) cell therapy, it seems so vital to find new useful therapies against cancers. Breast cancer is the second main cause of cancer death among women. As it is impossible for a majority of patients to receive NK cell therapy, an attempt was made to establish a low-cost and efficient method for expanding and activating NK cells against breast cancer cell line (MCF7). Methods: NK cells were isolated from Peripheral Blood Mononuclear Cells (PBMCs) applying either MACS based NK cell enrichment kit or antibodies and complement as cytotoxic method. Then, the NK cells were cultured in Stem Cell Growth Medium (SCGM) with feeder layer (irradiated PBMCs) along with PHA or OKT3. IL-2, IL-15 and IL-21 were used to expand NK cells and finally their cytotoxic activity was investigated by flow cytometry. Results: Highly pure NK cells were obtained and no significant difference between the two isolation methods was found. Using IL-2 plus IL-15, the number of NK cells increased up to100 fold after 16 days. No significant effect was observed after IL-21 treatment. Conclusion: Our data indicated that cytotoxicity method can be considered a low-cost alternative for NK cell isolation kits. It seems that culturing NK cells for 14 days in either PHA or OKT3 supplemented SCGM medium would be more effective than culturing for 16 days in the presence of IL-21.

Published
2020

13. 'Peripheral blood Microchimerism in female renal recipients from male donors '

Author

Hakemi M, Najafi I, Ganji MR, Khosravi F, and Nikbin B "

Subjects
Allograft function, Microchimerism, Renal transplantation, Medicine (General), R5-920
Abstract

The relation between microchimerism and allograft tolerance is still a mystery. In this study we determined the presence of peripheral blood microchimerism (PBMC) in female renal transplant recipients from living male donors with second round polymerase chain reaction (PCR). Second round PCR was used to find Y chromocome products. The degree of PBMC in renal transplant recipinents must be below the rate of 1.104 and second round PCR provides the deterction of PBMC at the rate of 1.106. we divided our patients into two groups according to allograft function. Group 1 (16 patients) and normal allograft function. Group 2 (6 patients) had chronic allograft dysfunction. First PCR didn’t show PBMC. Second round PCR with SRY primers of Y chromosome showed PBMC in 13.22 (59%) of patients. PMBC was positive in 10.016 (62%) of patients in-group 1 and 3.6 (50%) of patients in group 2. There was acute rejection in 4.13 (30.7%) and 2.9 (22.2%) of patients with positive and negative PBMC, respectively, in our study, there was no significant correlation between the presence of PBMC and allograft function and the frequency or severity of rejection episodes.

Published
2001

16. Comparison of the expression levels of Fas and Apaf-1 genes in systemic sclerosis dermal fibroblasts

Author

Khojasteh, M. A., Alsahebfosoul, F., Mahdi Mahmoudi, Mahmoudi, M. B., Mostafaei, S., Ganjalikhani-Hakemi, M., and Gharibdoost, F.

Subjects
lcsh:R5-920, systemic sclerosis, case-control studies, Apaf-1, Fas, lcsh:Medicine (General), fibroblast
Abstract

Background: Systemic sclerosis (SSc) is an autoimmune rheumatic connective tissue disease. In normal wound healing process, fibroblasts are activated, proliferated and involved in tissue repair, and then removed by apoptosis. In systemic sclerosis, patient’s fibrosis occurs when fibroblasts become resistant to apoptosis and secrete a large amount of collagen and other extracellular matrixes. As the primary causes the disease are very complex and often unknown, it is necessary to consider or target the secondary causes of disease, such as the unresponsiveness of activated fibroblasts to apoptosis as the major factor in the creation and deployment of illness. In this study, we examined the expression levels of two key pro-apoptotic genes, Fas and Apaf-1, which are respectively involved in external and internal pathway of apoptosis. Methods: In a case-control study skin biopsy samples were obtained from 19 patients with diffuse SSc, and 16 healthy controls. Dermal fibroblasts were cultured and total RNA was isolated from cell populations using High Pure RNA Isolation Kit (Roche Applied Science, Mannheim, Germany), followed by cDNA synthesis using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., Massachusetts, USA). Real-time PCR was performed using SYBRGreen gene expression master mix (Takara Shuzo, Co., Ltd, Shiga, Japan) and specific primers for Fas and Apaf-1. Real-time data were analyzed using the (2-ΔCT)×1000 method. Statistical analysis was accomplished by using the SPSS software, v22 (IBM, Armonk, NY, USA). The P value less than 0.05 were recognized as a significant threshold. All data are represented as the mean ± SEM. Results: Our results showed no significant difference in Fas (P=0.8) and Apaf-1 (P=0.17) mRNA expression levels between skin fibroblasts of systemic sclerosis patients and healthy controls. Conclusion: In this study we observed no significant change in Apaf-1 and Fas mRNA levels in systemic sclerosis fibroblasts compared to control group. Hence, Apaf-1 and Fas are not transcriptionally activated in SSc fibroblasts. Further studies need to take place on protein levels and function of these proteins to confirm the mRNA transcription results.

Published
2016

17. Evaluation of Mutation in B cell Maturation Antigen (BCMA) Gene in Patients with Common Variable Immunodeficiency (CVID)

Author

Ansari, M., Ganjalikhani-Hakemi, M., Sherkat, R., reza, Yazdani, R., and Khosravi, S.

Subjects
lcsh:R5-920, lcsh:R, lcsh:Medicine, Plasma cell, lcsh:Medicine (General), B cell maturation antigen (BCMA), Common variable immune deficiency (CVID)
Abstract

Background: Common variable immune deficiency (CVID) is the commonest symptomatic primary immunodeficiency and represents a heterogenous collection of disorders resulting mostly in antibody deficiency and recurrent infections .The syndrome includes impaired B-cell maturation, impaired somatic hypermutation, reduced numbers of circulating memory and isotype-switched memory B cells, and absent or reduced plasma cells. B cell maturation antigen (BCMA) is a tumor necrosis family receptor superfamily member 17 (TNFRSF17), expressed only on B cell lines , and is essential for survival of long-lived plasma cells .The aim of this study was to evaluate mutations in BCMA in patients with CVID in compare with normal individuals in Isfahan, Iran. Methods: Blood samples were collected from 10 CVID patients with substitutive immunoglobulin therapy before immunoglobulins (Ig) infusion and 10 normal controls in ethylenediaminetetraacetic acid (EDTA) tubes then DNA samples were extracted and after the polymerase chain reaction (PCR) was done, samples were sequenced. Findings: After reviewing the results of the sequence and alignment of the sequences, no mutations in the gene were seen. Conclusion: In addition to the study of mutation in BCMA gene, BCMA gene and protein expression level should be considered to understand more aspects of this disease.

Published
2016

18. Investigating the Frequency of the Peripheral Blood B and Transitional B Cells in the Patients with Common Variable Immunodeficiency

Author

Alihassanzadeh, M., nahid eskandari, Ganjalikhani-Hakemi, M., and Sherkat, R.

Subjects
lcsh:R5-920, BAFF-R, B Transitional, lcsh:R, lcsh:Medicine, Plasma cell, Peripheral blood mononuclear cells (PBMC), lcsh:Medicine (General)
Abstract

Background: Common variable immunodeficiency (CVID) is a heterogeneous set of immunological abnormalities including decreased serum levels of antibodies (hypogammaglobolinemia), at least for two isotopes of immunoglobulin, and impaired antibody response to infection or vaccination. Thus, it is associated with increased susceptibility to infections. This study aimed to investigate the frequency of B cells in the patients with CVID in Isfahan city, Iran. Methods: Blood samples were collected from the patients with substitutive immunoglobulin (Ig) therapy before immunoglobulin infusion. Then, peripheral blood mononuclear cells (PBMC) were isolated via Ficoll-Hypaque density centrifugation. Flow cytometry method was employed to determine the frequency and phenotype of the B and transitional B cells using the antibodies of CD19-FITC (Exebio), CD24-PE (Exebio), and CD38 PE (BD Exebio). Findings: There was significant difference in the proportion of the peripheral blood B cells in the patients with CVID, compared to the healthy subjects (P < 0.001). But, there was insignificant difference in the proportion of the transitional B cells in the patients, compared to the healthy subjects (P = 0.267). Conclusion: The results show that there is insignificant difference in the proportion of the transitional B cells in the patients with CVID, compared to control group. However, more studies should be carried out concerning mutation in the involved genes to understand more aspects of this disease.

Published
2016

19. siRNA Delivery Improvement by Co-formulation of Different Modified Polymers in Erythroleukemic Cell Line K562

Author

Ganjalikhani Hakemi M and Maryam Hashemi

Subjects
siRNA delivery, lcsh:R, Transferrin, lcsh:Medicine, Original Article, OEI PEI siRNA delivery Suspended cells Transferrin, OEI, Suspended cells, PEI
Abstract

Objective(s): siRNA may be a very promising tool for treatment of various diseases especially in cancer therapy due to high specificity. One of the main hurdles applications of siRNAs in vivo is optimization of the delivery strategy, especially the carrier systems. The aim of this study was to optimize siRNA delivery into suspended erythroleukemic cell line K562. Materials and Methods: We applied polyethyleneimine (PEI) and oligoethyleneimine (OEI) derivatives alone or their co-formulation with different agents such as chloroquine (a drug known to alter lysosomal pH and thus to inhibit lysosomal degradation of macromolecules), DOPE (lipophilic agent), succinic acid (introduction of negatively charged to polymer) and transferrin (the ligand of transferring receptor which is over-expressed in many types of tumors and hematopoietic cells). Results: In this study it was shown that utilizing a combination of 70% OEI-HA10 (ten hexyl acrylate residues per one OEI chain) plus 30% of transferin-PEI with Luc-siRNA was highly effective for transfecting K562 cell. This co-formulation silenced luciferase activity up to 70% after short time without any significant inhibition in the luciferase activity in siCONTROL wells. Conclusion: In conclusion, the combination of modified PEI with transferrin and OEI by hexyl acrylate may increase siRNA delivery and reduce toxicity in hematopoietic suspended cells.

Published
2013

21. Correlation of OX40 ligand on B cells with serum total IgE and IL-4 levels by CD4+T cells in allergic rhinitis

Author

Fouladi, S., Masjedi, M., G. Hakemi, M., Ghasemi, R., and Eskandari, N.

Abstract

Allergic rhinitis (AR) is a classic Th2-mediated disease, with important contributions to the pathology of interleukins 4, 5, and 13. The co-stimulatory molecule of OX40 and its ligand interaction participate in the immune response by regulation of Th1/Th2 cells balance. Considering the paucity of information on the relation between OX40 ligand (OX40L) and AR, this study aimed to examine its expression on B lymphocytes.

Published
2019
Full Text
View/download PDF

28. Peritoneal dialysis II

Author

Yayar, O., primary, Buyukbakkal, M., additional, Eser, B., additional, Yildirim, T., additional, Ercan, Z., additional, Erdogan, B., additional, Kali, A., additional, Merhametsiz, O., additional, Haspulat, A., additional, Akdag, I., additional, Ayli, M. D., additional, Quach, T., additional, Tregaskis, P., additional, Menahem, S., additional, Koukounaras, J., additional, Mott, N., additional, Walker, R., additional, Zeiler, M., additional, Santarelli, S., additional, Degano, G., additional, Monteburini, T., additional, Agostinelli, R. M., additional, Marinelli, R., additional, Ceraudo, E., additional, Grzelak, T., additional, Kramkowska, M., additional, Walczak, M., additional, Czyzewska, K., additional, Guney, I., additional, Turkmen, K., additional, Yazici, R., additional, Arslan, S., additional, Altintepe, L., additional, Yeksan, M., additional, Vaduva, C., additional, Popa, S., additional, Mota, M., additional, Mota, E., additional, Wan Md Adnan, W. A. H., additional, Zaharan, N. L., additional, Moreiras-Plaza, M., additional, Blanco-Garcia, R., additional, Beato-Coo, L., additional, Cossio-Aranibar, C., additional, Martin-Baez, I., additional, Santos, M. T., additional, Fonseca, I., additional, Santos, O., additional, Aguiar, P., additional, Rocha, M. J., additional, Carvalho, M. J., additional, Cabrita, A., additional, Rodrigues, A., additional, Guo, Z., additional, Lai, X., additional, Theodoridis, M., additional, Panagoutsos, S., additional, Thodis, E., additional, Karanikas, M., additional, Mitrakas, A., additional, Kriki, P., additional, Kantartzi, K., additional, Passadakis, P., additional, Vargemezis, V., additional, Vakilzadeh, N., additional, Pruijm, M., additional, Burnier, M., additional, Halabi, G., additional, Azevedo, P., additional, Carvalho, M., additional, Laplante, S., additional, Rutherford, P., additional, Shutov, E., additional, Isachkina, A., additional, Gorelova, E., additional, Troya, M.-I., additional, Teixido, J., additional, Pedreira, G., additional, Del Rio, M., additional, Romero, R., additional, Bonet, J., additional, Zhang, X., additional, Ma, J., additional, Kim, Y., additional, Kim, J.-K., additional, Song, Y. R., additional, Kim, S. G., additional, Kim, H. J., additional, Eloot, S., additional, Vanholder, R., additional, Van Biesen, W., additional, Heaf, J., additional, Pedersen, C., additional, Elgborn, A., additional, Arabaci, T., additional, Emrem, G., additional, Keles, M., additional, Kizildag, A., additional, Martino, F., additional, Amici, G., additional, Rodighiero, M. P., additional, Crepaldi, C., additional, Ronco, C., additional, Tanaka, H., additional, Tsuneyoshi, S., additional, Yamasaki, K., additional, Daijo, Y., additional, Tatsumoto, N., additional, Al-Hilali, N., additional, Hussain, N., additional, Fathy, V., additional, Negm, H., additional, Alhilali, M., additional, Grzegorzewska, A., additional, Cieszynski, K., additional, Kaczmarek, A., additional, Sowinska, A., additional, Soleymanian, T., additional, Najafi, I., additional, Ganji, M. R., additional, Ahmadi, F., additional, Saddadi, F., additional, Hakemi, M., additional, Amini, M., additional, Tong, L. N. M. N., additional, Yongcheng, H. N. M. N., additional, Qijun, W. N. M. N., additional, Shaodong, L. N. M. N., additional, Velioglu, A., additional, Albaz, M., additional, Arikan, H., additional, Tuglular, S., additional, Ozener, C., additional, Bakirdogen, S., additional, Eren, N., additional, Mehtap, O., additional, Bek, S. G., additional, Cekmen, M. B., additional, Yilmaz, A., additional, Cabana Carcasi, M. L. L., additional, Fernandez Ferreiro, A., additional, Fidalgo Diaz, M., additional, Becerra Mosquera, V., additional, Alonso Valente, R., additional, Buttigieg, J., additional, Borg Cauchi, A., additional, Rogers, M., additional, Buhagiar, L., additional, Farrugia Agius, J., additional, Vella, M. P., additional, Farrugia, E., additional, Han, J. H., additional, Kim, H. R., additional, Ko, K. I., additional, Kim, C. H., additional, Koo, H. M., additional, Doh, F. M., additional, Lee, M. J., additional, Oh, H. J., additional, Han, S. H., additional, Yoo, T.-H., additional, Kang, S.-W., additional, Choi, K. H., additional, Sikorska, D., additional, Frankiewicz, D., additional, Klysz, P., additional, Schwermer, K., additional, Hoppe, K., additional, Nealis, J., additional, Kaczmarek, J., additional, Baum, E., additional, Wanic-Kossowska, M., additional, Pawlaczyk, K., additional, Oko, A., additional, Hiss, M., additional, Gerstein, F., additional, Haller, H., additional, Gueler, F., additional, Fukasawa, M., additional, Manabe, T., additional, Wan, Q., additional, He, Y., additional, Zhu, D., additional, Li, J., additional, Xu, H., additional, Yayar, O., additional, Oztemel, A., additional, Pilcevic, D., additional, Kovacevic, Z., additional, Maksic, D., additional, Paunic, Z., additional, Tadic-Pilcevic, J., additional, Mijuskovic, M., additional, Petrovic, M., additional, Obrencevic, K., additional, Rabrenovic, V., additional, Ignjatovic, L., additional, Terzic, B., additional, Jovanovic, D., additional, Chang, C.-H., additional, Chang, Y.-S., additional, Busuioc, M., additional, Guerraoui, A., additional, Caillette-Beaudoin, A., additional, Bahte, S. K., additional, Kielstein, J. T., additional, Polinder-Bos, H., additional, Emmelot-Vonk, M., additional, and Gaillard, C., additional

Published
2013
Full Text
View/download PDF

31. Renal histopathology

Author

Saddadi, F., primary, Najafi, I., additional, Hakemi, M., additional, Jahani, M., additional, Ali Moghadam, K., additional, Ghavamzadeh, A., additional, Soleimanian, T., additional, Perkowska-Ptasinska, A., additional, Wagrowska-Danilewicz, M., additional, Danilewicz, M., additional, Halon, A., additional, Komuda, E., additional, Karkoszka, H., additional, Andrzejewska, A., additional, Okon, K., additional, Kurnatowska, I., additional, Krasnicka, M., additional, Hryszko, T., additional, Kusztal, M., additional, Wiechecka-Korenkiewicz, J., additional, Marcinkowska, E., additional, Korenkiewicz, J., additional, Marszalek, A., additional, Sypniewska, G., additional, Manitius, J., additional, Cappuccino, L., additional, Verzola, D., additional, Tosetti, F., additional, Marre, S., additional, Villaggio, B., additional, Salvidio, G., additional, Garibotto, G., additional, Pasquariello, A., additional, Innocenti, M., additional, Pasquariello, G., additional, Mattei, P., additional, Samoni, S., additional, Sami, N., additional, Cupisti, A., additional, Malvar, B., additional, Viana, H., additional, Galvao, M., additional, Carvalho, F., additional, Oksa, A., additional, Demes, M., additional, Danis, D., additional, Hilhorst, M., additional, van Paassen, P., additional, van Breda Vriesman, P., additional, Cohen Tervaert, J. W., additional, Ciszek, M., additional, Urbanowicz, A., additional, Kwiatkowski, A., additional, Durlik, M., additional, Saito, T., additional, Kawano, M., additional, Saeki, T., additional, Nishi, S., additional, Yamaguchi, Y., additional, Hisano, S., additional, Nakashima, H., additional, Yamanaka, N., additional, Oh, S.-W., additional, Chin, H. J., additional, Na, K. Y., additional, Chae, D.-W., additional, Ozkan, G., additional, Ulusoy, S., additional, Ersoz, S., additional, Orem, A., additional, Alkanat, M., additional, Yucesan, F., additional, Kaynar, K., additional, Al, S., additional, Simic Ogrziovic, S., additional, Bojic, S., additional, Basta Jovanovic, G., additional, Kotur Stevuljevic, J., additional, Dosaj, V., additional, Lezaic, V., additional, Yagisawa, T., additional, Kimura, T., additional, Ishikawa, N., additional, and Yashi, M., additional

Published
2011
Full Text
View/download PDF

32. The possibility of miR-20a/b & miR-93 role in differentiation of naïve CD4+ to Th17 cells in multiple sclerosis.

Author

Naghavian, R., Honardoost, M. A., Hosseini, A., Ghaedi, K., Etemadifar, M., Nasr Esfahani, M. H., and Ganjalikhani Hakemi, M.

Subjects
AUTOIMMUNE diseases, CELLS, GENES, GENETICS, MULTIPLE sclerosis
Abstract

Background and Objectives Multiple sclerosis (MS) is an autoimmune neurodegenerative disease in which the body's natural defense system attacks myelin on neuronal cells. One of the most important immune system cells involved in MS is Th17 which is one of the main cells involved in most of autoimmune diseases. Recently, microRNAs (miRNAs) have been remarkably used in treating many kinds of diseases. MicroRNAs are endogenous 22-25 nt RNAs playing an important regulatory roles in cellular and developmental processes. Materials and Methods The goal of this article is to determine miRNAs which possibly have the most effect in the pathway of differentiation to Th17 cells by using miRWalk database and candidate microRNAs that can suppress this pathway and limit the disease's symptoms. Our in-silico studies identified the possible role of several miRNAs in differentiation of naïve CD4+ cells to Th17 cells. Results miR-93,miR-20a/b are probably applicable to inhibit the differentiation of naïve T cells into Th17 cells to reduce the progress of MS and also to be used as markers of diagnosis of MS in early stages. Conclusions According to our results miR-20a/b&miR-93 can possibly be the key miRNAs, inhibiting the progression of MS by preventing the differentiation to Th17 cells. [ABSTRACT FROM AUTHOR]

Published
2015

36. Comparison of B-cells differentiation to plasmablasts at presence of anti-human CD40 and anti-immunoglobulin M f (Ab)'2 or lipopolysaccharide and anti-human CD40 stimulators (in-vitro)

Author

Afshar-Qasemloo, S., Nafiseh Esmaeil, Ganjalikhani-Hakemi, M., Rezaei, A., Yazdani, R., and Abbasi-Rad, F.

Subjects
Lipopolysaccharides, lcsh:R5-920, B-cell differentiation factor receptor, lcsh:R, B-cells, lcsh:Medicine, Flow cytometry, lcsh:Medicine (General), Plasmablast
Abstract

Background: Transformation and differentiation of activated B-cell to plasmacells and also memory cells depend on signaling from B-cell receptors. The signals from antigen and cytokine receptors on the surface of B cells lead to induce the expression of specific transcription factors, which finally determine the fate of B cells. Methods: Peripheral blood mononuclear cells (PBMC) were isolated via ficoll gradient and then purified B cells were separated using magnetic-activated cell sorting (MACS). Pure B cells were cultured in Roswell Park Memorial Institute 1640 (RPMI1640) culture media at the presence of purified anti-human CD40 antibody and anti-immunoglobulin M f (ab)´2 or lipopolysaccharide (LPS) and anti-human CD40 antibody that induced B-cells differentiation to plasmablasts which was assessed with 3 markers (CD38+, CD27+, IgM-) and analyzed via flow cytometry. Findings: In stimulation of B cells with purified anti-human CD40 antibody and anti-IgM f (ab)´2 or LPS through cross-linking B-cell receptor, the majority of B cells remained alive and differentiated to another lineage of B cells (plasmablast: CD38+, CD27+, IgM-). There was no significant statistical difference between expressions of plasmablast markers in two states of stimulation. Conclusion: B cells can be stimulated and differentiated to plasmablasts in vitro similar to in vivo condition. However, to achieve the best outcome in the differentiation of B cells, we should consider the nature of stimulator, the time of incubation, and the type of stimulators.

37. Comparing in-vitro effects of two immunosuppressive drugs on the expression of Foxp3 from Naïve CD4+ T Cells

Author

Shajanian, S., Marjan Gharagozloo, Ganjalikhani-Hakemi, M., and Rafiee, M.

Subjects
lcsh:R5-920, Foxp3, lcsh:R, lcsh:Medicine, Regulatory T cells (Treg), Rapamycin, lcsh:Medicine (General), Mammalian target of rapamycin (mTOR), Silymarin
Abstract

Background: Many studies showed that regulatory T cells (Tregs) have immunosuppressive effects on immune responses in transplantation and autoimmune disease. Silymarin (isolated from milk thistle or silybum marianum plant) is a flavolignan complex with anti-inflammatory, hepatoprotective, antioxidant and immunomodulatory activities. Previous studies in our group revealed inhibition effect of silymarin on mammalian target of rapamycin (mTOR) activity in activated T cells. Among immunosuppressive drugs, rapamycin can inhibit mTOR, results in Foxp3 expression, Tregs expansion and conventional T cells inhibition. In this study, the effect of silymarin on in-vitro generation of CD4+Foxp3+ cells, in comparison with rapamycin, was evaluated. Methods: Naïve CD4+ T cells were separated from healthy individuals’ peripheral blood mononuclear cells (PBMCs) and activated with monoclonal antibody anti-CD3 and anti-CD28 for 18 hours in Roswell Park Memorial Institute (RPMI) complete medium. Then, incubation was continued with adding Interlukin-2 (IL-2) and silymarin or its control, dimethyl sulfoxide (DMSO), or cultured in present or absent of rapamycin for 3 days. Cells were harvested and stained with anti-CD4 and anti-FoxP3 antibodies for flow cytometry. Findings: Silymarin increased CD4+Foxp3+ T cells compared with its control, DMSO, and with rapamycin after three days of culture of naïve T cells (P 0.05). Conclusion: Given the importance of replacement less harmful medicine and Tregs role in regulating immune system, silymarin, as aTreg generation drug, can be used in the treatment of autoimmune diseases and even in organ transplantation.

41. Evaluation of il-17 gene expression in the peripheral blood of patients with common variable immunodeficiency

Author

Yazdani, R., Hakemi, M. G., Sherkat, R., Masjedi, M., Zarkesh, H., and Mohsen Hosseini

Subjects
IL-17, Real time-PCR, lcsh:R5-920, Cytokin, lcsh:R, lcsh:Medicine, Th17, lcsh:Medicine (General), Common variable immunodeficiency
Abstract

مقدمه: سلول TH17 با تولید IL-17 می‌تواند سبب افزایش تولید دو سایتوکین BAFF و APRIL شود که نقش مهمی در بقا و فعال شدن سلول B، و در نتیجه، پاسخ‌های ایمنی هومورال دارند. نارسایی ایمنی رایج متغیر (Common variable immunodeficiency یا CVID)، یکی از بیماری‌های نقص ایمنی اولیه می‌باشد که با کاهش سطح آنتی‌بادی‌ها (نارسایی ایمنی هومورال) همراه است. فراوانی افراد مبتلا به CVID در جمعیت‌های مختلف در محدوده‌ی 1:10000 تا 1:50000 گزارش شده است. هدف از این مطالعه، مقایسه‌ی میانگین بیان ژن IL-17 در بیماران مبتلا به CVID با افراد سالم بود. روش‌ها: ابتدا 2 میلی‌لیتر خون کامل از 10 بیمار مبتلا به CVID و 10 فرد سالم گرفته و سپس تمام mRNA موجود در این نمونه‌ها جدا شد. پس از ساختن cDNA از روی mRNA، میزان بیان ژن IL-17 را با استفاده از روش Real Time-PCR سنجیدیم. یافته‌ها: میزان بیان ژن IL-17 در بیماران مبتلا به CVID نسبت به افراد شاهد کاهش یافت که البته این کاهش از لحاظ آماری معنی‌دار نبود (195/0 = P). نتیجه‌گیری: در این پژوهش نشان دادیم که میزان بیان ژن IL-17 در خون بیماران مبتلا به CVID نسبت به افراد سالم کاهش داشت؛ این موضوع دلیلی بر نقص تولید این سایتوکین است و می‌تواند دلیل نارسایی پاسخ ایمنی هومورال در این افراد باشد.

43. miR-370 expression analysis in breast cancer

Author

Mollainezhad, H., nahid eskandari, Pourazar, A., Andalib, A., Salehi, M., and Ganjalikhani-Hakemi, M.

Subjects
MicroRNAs, lcsh:R5-920, Breast cancer, lcsh:R, Quantitative real-time polymerase chain reaction, lcsh:Medicine, lcsh:Medicine (General)
Abstract

Background: MicroRNAs (MiRNAs) are 21-24 nucleotides which have different levels of expression between tumors and normal tissues. In this study, we analyzed the expression level of miR-370 in different stages and grades of human breast cancer tissues compared with adjacent normal tissues. Methods: In this case-control study, the expression of miR-370 on 22 tissue samples (tumor and normal) from patients with breast cancer was investigated via quantitative real-time polymerase chain reaction method. Findings: miR-370 expression showed a significant increase in tumor tissues compared to normal tissues (P = 0.001) as well as in cancer tissues at stage III (P = 0.004) and grade 3 (P = 0.011) than in other stages. Conclusion: According to evaluation of miR-370 expression in different stages and grades and its relation to more advanced tumor stages/grades, it can possibility act as oncomiRNA in breast cancer. It may be suggested as a prognostic biomarker or therapeutic target in breast cancer, too.

45. Evaluation of IL-17 gene expression in peripheral blood and sputum of asthma patients and healthy individuals

Author

Yazdani, R., Hakemi, M. G., Sherkat, R., reza, Farahani, R., and Beiranvand, B.

Subjects
IL-17, lcsh:R5-920, mRNA, Th17, asthma, lcsh:Medicine (General), respiratory tract diseases
Abstract

Background: Asthma as an airway disease is identified by increase network respon-siveness of the trachea and bronchus to a specific stimulus. Th17 cells through produc-tion of IL-17 have important role in inflammation and autoimmune diseases .In some studies has been shown which IL-17 as major cytokine of Th17 probably has im-portant role in the pathogenesis of allergy and asthma. Methods: Total mRNA extracted from whole blood samples and sputum of 23 asthma patients and 23 normal controls. Then, total RNA was converted into cDNA according to the manufacturer’s instructions. Finally, the transcript levels of IL-17 were quanti-fied by the real-time quantitative PCR. Twenty-three patients with asthma were diag-nosed and selected according to the global initiative for asthma (GINA) and none of the patients had taken the medication at least three week before sampling. Healthy in-dividuals did not have any history of allergy, asthma and other inflammatory diseases at the time of sampling. All of experiments have done in Isfahan University of Medical Sciences, Iran during May to February, 2013. Results: This study showed a significant increase in transcript levels of IL-17 in the blood (287±79 versus 1/18±0/13) and sputum samples of the patients (64±28 versus 0/9±0/1) in comparison with normal individuals (P= 0.000, P= 0.029 respectively). It al-so revealed that the expression levels of the cytokines in the serum samples of the asthmatics were significantly more than their levels in patient’s sputum samples (P= 0.000). However, there was no significant difference between the cytokines expression levels in serum samples and sputum samples of the controls (P> 0.05). Conclusion: In this study, we showed which the expression of IL-17 was increased in serum and sputum of asthmatic patients compared to healthy controls, this could re-sult in elevation of neutrophils population and activation of pulmonary neutrophil.

49. Positive and negative regulation of Th17 cell differentiation: Evaluating the impact of RORC2

Author

Hakemi, M. G., Ghaedi, K., Homayouni, V., Andalib, A., Sayed Mohsen Hosseini, and Rezaei, A.

Subjects
IL-17, siRNA, Immunology, lcsh:R, Genetics, lcsh:Medicine, Original Article, lcsh:Q, Th17, lcsh:Science, IL-23R, RORC2
Abstract

Objective: Th17 cells are known to be involved in some types of inflammations and autoimmune disorders. RORC2 is the key transcription factor coordinating Th17 cell differentiation. Thus, blocking RORC2 may be useful in suppressing Th17-dependent inflammatory processes. The aim was to silence RORC2 by specific siRNAs in naïve T cells differentiating to Th17. Time-dependent expression of RORC2 as well as IL-17 and IL-23R were considered before and after RORC2 silencing. Materials and Methods: In this experimental study, naïve CD4+ T cells were isolated from human cord blood samples. Cytokines TGFβ plus IL-6 and IL-23 were used to polarize the naïve T cells to Th17 cells in X-VIVO 15 serum free medium. A mixture of three siRNAs specific for RORC2 was applied for blocking its expression. RORC2, IL-17 and IL-23R mRNA and protein levels were measured using qRT-PCR, ELISA and flow cytometry techniques. Pearson correlation and one-way ANOVA were used for statistical analyses. Results: Significant correlations were obtained in time-dependent analysis of IL-17 and IL-23R expression in relation with RORC2 (R=0.87 and 0.89 respectively, p

Catalog

Books, media, physical & digital resources
See catalog results